Cargando…
Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting
BACKGROUND: To identify risk factors for being a “reduced responder” to ranibizumab treatment in a clinical setting in patients with neovascular age-related macular degeneration. METHODS: This retrospective study included 165 eyes of 165 consecutive patients with choroidal neovascularisation seconda...
Autores principales: | Korb, Christina, Zwiener, Isabella, Lorenz, Katrin, Mirshahi, Alireza, Pfeiffer, Norbert, Stoffelns, Bernhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878195/ https://www.ncbi.nlm.nih.gov/pubmed/24359591 http://dx.doi.org/10.1186/1471-2415-13-84 |
Ejemplares similares
-
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008) -
Serum Autoantibodies in Patients with Dry and Wet Age-Related Macular Degeneration
por: Korb, Christina A., et al.
Publicado: (2023) -
Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022) -
Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)